Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 96.43 USD 3.84% Market Closed
Market Cap: 240.9B USD

Relative Value

The Relative Value of one MRK stock under the Base Case scenario is 133.54 USD. Compared to the current market price of 96.43 USD, Merck & Co Inc is Undervalued by 28%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRK Relative Value
Base Case
133.54 USD
Undervaluation 28%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
84
vs Industry
33
Median 3Y
4.3
Median 5Y
4
Industry
2.7
Forward
3.7
vs History
90
vs Industry
33
Median 3Y
20.6
Median 5Y
20.6
Industry
22.3
Forward
10.6
vs History
57
vs Industry
32
Median 3Y
14
Median 5Y
14.3
Industry
16.8
vs History
65
vs Industry
26
Median 3Y
17.4
Median 5Y
17.6
Industry
23.1
vs History
87
vs Industry
14
Median 3Y
5.8
Median 5Y
5.6
Industry
2.3
vs History
82
vs Industry
31
Median 3Y
4.7
Median 5Y
4.4
Industry
2.9
Forward
4
vs History
85
vs Industry
41
Median 3Y
6.4
Median 5Y
6.3
Industry
5.6
vs History
85
vs Industry
35
Median 3Y
11.3
Median 5Y
11.3
Industry
13.2
Forward
8.6
vs History
85
vs Industry
35
Median 3Y
13.4
Median 5Y
13.6
Industry
16.9
Forward
9.6
vs History
57
vs Industry
30
Median 3Y
15.1
Median 5Y
15.7
Industry
15.6
vs History
58
vs Industry
25
Median 3Y
19.4
Median 5Y
21.2
Industry
18.4
vs History
69
vs Industry
29
Median 3Y
3
Median 5Y
2.5
Industry
1.9

Multiples Across Competitors

MRK Competitors Multiples
Merck & Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Merck & Co Inc
NYSE:MRK
240.1B USD 3.7 12.6 9 10.7
US
Eli Lilly and Co
NYSE:LLY
971B USD 16.3 52.9 35.4 38
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
479.2B USD 5.2 19.1 15.6 20.3
CH
Roche Holding AG
SIX:ROG
245.2B CHF 4 26 11.7 13.2
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP 4.7 29.2 107.9 157.9
CH
Novartis AG
SIX:NOVN
195.9B CHF 4.4 17 10.8 14
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.7
IE
Endo International PLC
LSE:0Y5F
202B USD 87.1 -69.1 320.4 803.4
US
Pfizer Inc
NYSE:PFE
142.9B USD 2.3 14.7 7.4 10.1
FR
Sanofi SA
PAR:SAN
106.3B EUR 1.6 7.7 7 7
P/E Multiple
Earnings Growth PEG
US
Merck & Co Inc
NYSE:MRK
Average P/E: 21.4
12.6
15%
0.8
US
Eli Lilly and Co
NYSE:LLY
52.9
50%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.2
38%
0.8
CH
Novartis AG
SIX:NOVN
17
18%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
31%
0.5
FR
Sanofi SA
PAR:SAN
7.7
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Merck & Co Inc
NYSE:MRK
Average EV/EBITDA: 398.3
9
7%
1.3
US
Eli Lilly and Co
NYSE:LLY
35.4
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.6
8%
2
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
107.9
10%
10.8
CH
Novartis AG
SIX:NOVN
10.8
6%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
6%
1.5
IE
E
Endo International PLC
LSE:0Y5F
320.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
FR
Sanofi SA
PAR:SAN
7
9%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Merck & Co Inc
NYSE:MRK
Average EV/EBIT: 1 708
10.7
9%
1.2
US
Eli Lilly and Co
NYSE:LLY
38
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.3
14%
1.4
CH
Roche Holding AG
SIX:ROG
13.2
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
157.9
22%
7.2
CH
Novartis AG
SIX:NOVN
14
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
6%
1.8
IE
E
Endo International PLC
LSE:0Y5F
803.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1
FR
Sanofi SA
PAR:SAN
7
15%
0.5